Glen Harbor Capital Management’s Myriad Genetics MYGN Stock Holding History

Glen Harbor Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$293K	Buy	10,230 +550	+6%	+$16K	0.01%	891
2019 Q2	$269K	Buy	9,680 +418	+5%	+$11.8K	0.01%	930
2019 Q1	$308K	Hold	9,262	–	–	0.01%	854
2018 Q4	$269K	Hold	9,262	–	–	0.01%	855
2018 Q3	$426K	Buy	9,262 +594	+7%	+$26.4K	0.01%	786
2018 Q2	$324K	Hold	8,668	–	–	0.01%	809
2018 Q1	$256K	Buy	8,668 +1,342	+18%	+$45.4K	0.01%	883
2017 Q4	$252K	Buy	7,326 +1,188	+19%	+$40.1K	0.01%	892
2017 Q3	$222K	Buy	6,138 +990	+19%	+$28.2K	0.01%	872
2017 Q2	$133K	Buy	5,148 +2,332	+83%	+$49.5K	﹤0.01%	994
2017 Q1	$54K	Buy	+2,816	New	+$49.9K	﹤0.01%	1111

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glen Harbor Capital Management's MYGN Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Myriad Genetics (MYGN) stake by 5.7% in Q3 2019, buying an estimated $16K and bringing the position to 10,230 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #891.

Glen Harbor Capital Management first reported a position in MYGN in Q1 2017 and has held it in 11 quarters since. The position peaked at $426K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Glen Harbor Capital Management held 10,230 shares of Myriad Genetics worth $293K as of Q3 2019.
Glen Harbor Capital Management bought 550 Myriad Genetics shares in Q3 2019, an estimated $16K.
Myriad Genetics made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #891 holding.
Glen Harbor Capital Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 11 quarters since.
Glen Harbor Capital Management's Myriad Genetics position peaked at $426K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.